WEST PHARMACEUTICAL SERVICES

West Pharmaceutical Services CFO’s Form 4 filing shows a modest net rise in ownership after share trades and RSU conversions, highlighting insider confidence and SEC‑compliant governance.

West Pharmaceutical Services cyber‑breach reveals the growing risk to pharma data security—why operational resilience, IP protection, and strategic M&A matter for industry survival.

West Pharmaceutical Services shines in income‑focused ETFs, delivering stable dividends and cutting‑edge drug delivery tech for biopharma.

West Pharmaceutical Services Q2 2026: modest sales growth, $210 M operating income, and a $112 M AbbVie sale boosting cash & future innovation.

West Pharmaceutical Services Q2 2026: $800 M net sales, $2.00+ EPS, strong cash flow, and a mid‑$3 B sales outlook driven by high‑growth injectable drug demand.